Antibacterial Agents TRIZ Cases

Fermentation and HPLC purification yield a stable octapeptide that combats resistant bacteria with broad-spectrum activity and low hemolysis.

Recombinant, chimeric, and antibody-based proteins control free TGF-β growth factor levels by stabilizing or releasing latent complexes.

C25 ansa-chain rifabutin analogs block ADP-ribosylation inactivation, restoring activity against resistant M. abscessus.

Epitope-linked recombinant polypeptides selectively stimulate or inhibit disease-relevant T cells, reducing global immunotoxicity in cancer and autoimmunity.

Encapsulating exogenous therapeutics in recombinant Spirulina protects them from pH and enzyme degradation while lowering production cost.

C7-fluoro tetracycline variants use targeted substituent changes to improve activity against resistant bacterial species.

Odd-carbon fatty acids strengthen intestinal barriers and immune homeostasis while avoiding complex multi-component formulations.

A surfactant-based nanocontainer with an inorganic shell improves aqueous delivery, loading, and stability of lipophilic antibiotics.

Hydrogen-bonded self-assembly with cyclobutanedicarboxylic acid improves carboplatin stability, bioavailability, and toxicity control.

Specific amino acid changes and a ring structure help this polymyxin-like decapeptide bind modified lipid A and inhibit resistant Gram-negative bacteria.

By blocking ENPP1-driven 2'3'-cGAMP hydrolysis, these compounds preserve STING activation and strengthen anti-tumor immune response.

Side-chain acyl tuning in cyclic alkaline lipopeptides improves Gram-negative antibacterial activity while reducing nephrotoxicity.

Combining Lactobacillus plantarum L-137 with fatty acids boosts IL-12, strengthens immune response, and adds bacteriostatic feed value.

RNA-seq-guided antigen selection identifies immunogenic N. gonorrhoeae polypeptides to improve mucosal protection across strains.

Novel lactivicin compounds use siderophore-like uptake and β-lactamase resistance to treat Gram-negative bacterial infections.

A defined mix of beneficial bacterial strains restores microbiome balance and lowers pathogen overgrowth risk in C. difficile treatment.

Antibodies block class A β-lactamases from resistant bacteria, protecting β-lactam antibiotics and improving treatment at low concentrations.

By blocking PqsR-mediated quorum sensing, these lactams suppress Pseudomonas biofilms in chronic wounds without driving resistance.

A multi-component fragrance blend inhibits replication, biofilms, quorum sensing, and toxins to help control resistant infectious pathogens.

A tripeptide-guided Hip1 inhibitor uses a C-terminal electrophilic warhead to inactivate the enzyme, aiming to shorten drug-resistant TB treatment.

A hypotonic acid oxidizing hypochlorous acid solution cuts wound healing time while lowering bacterial and viral loads in difficult skin lesions.

A Cyclocarya paliurus leaf flavonoid extract shows strong bactericidal activity against MRSA, offering a plant-based route beyond beta-lactam resistance.

Converting phenol actives into phenolate salts improves aqueous stability, solubility, and bioavailability for oral and skin delivery.

Surface-exposed Pseudomonas proteins are screened in silico to find protective vaccine targets faster and avoid abundant but weak antigens.

Novel synthesis routes produce metallo-β-lactamase inhibitors that protect carbapenems against resistant Gram-negative bacteria.

Orthosomycin compounds delivered through the teat canal treat resistant mastitis in dairy animals while maintaining milk activity and low systemic exposure.

Combining HSC transfer with PD-1, PD-L1, or VISTA blockade boosts IFNγ-positive T cells and supports long-term regression in resistant cancers.

Selective compounds block the DCN1-UBC12 interaction to regulate Cullin neddylation while reducing toxicity seen with broad UPS inhibitors.

Non-pathogenic germination-competent spores restore diverse gut microbiota functions, helping prevent GI disease and reduce pathogen susceptibility.

Diaminoguanidine feed compositions treat bacterial infections in farmed animals while lowering toxicity, drug residues, and resistance risk.

Combining vaborbactam with meropenem restores activity against CRE and other gram-negative infections in immunocompromised patients.

Engineered LAG-3-binding antibodies use defined CDR regions and bispecific formats to overcome immune suppression and strengthen anti-tumor responses.

Programmable nucleases cut microbial genomes for log-scale killing within minutes and sustained effect for hours without compromising concurrent therapies.

Programmable CRISPR/Cas nucleases cut microbial genomes for rapid killing and sustained infection or biofouling control with less therapy interference.

C25 triazolo acetate ester modification of rifabutin improves activity against M. abscessus and broadens antibacterial coverage.

Quorum-sensing lactams block PqsR signaling and biofilm formation in Pseudomonas, reducing chronic infection resistance pressure.

Heat-shocked serum-free MSC culture raises CD81 and miR-4516 in extracellular vesicles, improving anti-inflammatory and fibrosis therapy.

Novel heteroaryl-substituted imidazole compounds target drug-resistant Acinetobacter baumannii and expand treatment options for severe infections.

Phage cocktails target and lyse Pseudomonas aeruginosa while staying active in lung fluids, resisting sputum inactivation, and reducing biofilms.

A polymer-stabilized spray-dried mRNA lipid nanoparticle powder prevents aggregation and preserves integrity for inhaled delivery.

Cell-free co-expression and self-assembly of homologous phage proteins expands host range while avoiding complex genome modification.

Siderophore-linked vancomycin uses iron transport uptake to cross Gram-negative outer membranes and extend activity against resistant bacteria.

High-affinity monoclonal antibodies improve AM and LAM detection sensitivity and specificity in simple lateral flow TB tests for resource-limited settings.

Engineered bispecific antibodies recruit C1q directly to target antigens, overcoming density-dependent complement activation for cell lysis.

Combining Lactobacillus plantarum L-137 with selected fatty acids boosts IL-12 production, immune stimulation, and bacteriostasis in feed.

Diaminoguanidine feed compositions treat bacterial infections in farmed animals while lowering drug residue and resistance risks.

A five-plus engineered phage cocktail kills diverse M. tuberculosis strains, addressing drug resistance and potentially shortening treatment.

Boronic acid compounds block β-lactamase enzymes to restore antibiotic activity and improve treatment of resistant bacterial infections.

A consensus α-core formula unifies key peptide features to identify and validate novel alpha-helical antimicrobial peptides.